Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Clinical/translational cancer immunotherapy

Original research

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy

Online download statistics by month:

Online download statistics by month: August 2022 to August 2024

	Abstract	Full	Pdf
Aug 2022	1481	1504	330
Sep 2022	808	823	223
Oct 2022	369	375	151
Nov 2022	359	359	67
Dec 2022	137	141	59
Jan 2023	220	225	55
Feb 2023	197	201	70
Mar 2023	180	180	62
Apr 2023	128	130	53
May 2023	112	114	72
Jun 2023	91	92	37
Jul 2023	97	97	32
Aug 2023	76	77	32
Sep 2023	78	78	37
Oct 2023	87	88	39
Nov 2023	73	73	23
Dec 2023	83	85	41
Jan 2024	60	60	33
Feb 2024	68	68	30
Mar 2024	105	107	75
Apr 2024	96	97	44
May 2024	99	98	48
Jun 2024	67	67	24
Jul 2024	65	67	29
Aug 2024	60	58	25
Total	5196	5264	1691